Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. (I) wherein each symbol is as described in the specification, or a salt thereof.
1. A compound represented by the formula (I):
wherein
R 1 is an optionally substituted 5- or 6-membered cyclic group or an optionally substituted C 1-6 alkyl group;
R 2 and R 3 are the same or different and each is a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 1-6 alkoxy group, or an optionally substituted C 3-6 cycloalkyl group;
R 4 is a halogen atom, a cyano group, an optionally substituted C 1-6 alkyl group, an optionally substituted C 1-6 alkoxy group, an optionally substituted carbamoyl group, or an optionally substituted 3- to 8-membered cyclic group; and
Ring A is an optionally further substituted 6-membered aromatic ring,
or a salt thereof.
2. The compound according to claim 1 , wherein R 1 is
(1) an optionally substituted phenyl group,
(2) an optionally substituted C 5-6 cycloalkyl group,
(3) an optionally substituted 5- or 6-membered non-aromatic heterocyclic group,
(4) an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group, or
(5) an optionally substituted C 1-6 alkyl group,
or a salt thereof.
3. The compound according to claim 1 , wherein R 4 is
(1) a halogen atom,
(2) a cyano group,
(3) a C 1-6 alkyl group,
(4) an optionally substituted C 1-6 alkoxy group,
(5) an optionally substituted carbamoyl group, or
(6) an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group,
or a salt thereof.
4. The compound according to claim 1 , wherein Ring A is a 6-membered aromatic ring optionally further substituted by 1 to 3 substituents, in addition to R 4 , selected from the group consisting of
(a) a halogen atom,
(b) a C 1-6 alkyl group, and
(c) a C 1-6 alkoxy group,
or a salt thereof.
5. The compound according to claim 1 , wherein
R 1 is
(1) an optionally substituted phenyl group,
(2) an optionally substituted C 5-6 cycloalkyl group,
(3) an optionally substituted 5- or 6-membered non-aromatic heterocyclic group,
(4) an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group, or
(5) an optionally substituted C 1-6 alkyl group;
R 2 is
(1) a hydrogen atom,
(2) a halogen atom, or
(3) an optionally substituted C 1-6 alkyl group;
R 3 is
1) a hydrogen atom,
(2) a halogen atom,
(3) a cyano group,
(4) an optionally substituted C 1-6 alkyl group,
(5) a C 1-6 alkoxy group, or
(6) a C 3-6 cycloalkyl group;
R 4 is
(1) a halogen atom,
(2) a cyano group,
(3) a C 1-6 alkyl group,
(4) an optionally substituted C 1-6 alkoxy group,
(5) an optionally substituted carbamoyl group, or
(6) an optionally substituted 5- or 6-membered monocyclic aromatic heterocyclic group; and
Ring A is a 6-membered aromatic ring optionally further substituted by 1 to 3 substituents, in addition to R 4 , selected from the group consisting of
(a) a halogen atom,
(b) a C 1-6 alkyl group, and
(c) a C 1-6 alkoxy group,
or a salt thereof.
6. The compound according to claim 1 , wherein
R 1 is
(1) a phenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of
(i) a halogen atom, and
(ii) a cyano group,
(2) a C 5-6 cycloalkyl group optionally substituted by 1 to 3 substituents selected from the group consisting of
(i) a hydroxy group,
(ii) a C 1-6 alkyl group optionally substituted by from 1 to 3 hydroxy groups, and
(iii) a C 1-6 alkoxy group,
(3) a 5- or 6-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 hydroxy groups,
(4) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 halogen atoms, or
(5) a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from the group consisting of
(i) a hydroxy group, and
(ii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group;
R 2 is
(1) a hydrogen atom,
(2) a halogen atom, or
(3) a C 1-6 alkyl group;
R 3 is
(1) a hydrogen atom,
(2) a halogen atom,
(3) a cyano group,
(4) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(5) a C 1-6 alkoxy group, or
(6) a C 3-6 cycloalkyl group;
R 4 is
(1) a halogen atom,
(2) a cyano group,
(3) a C 1-6 alkyl group,
(4) a C 1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms,
(5) a carbamoyl group,
(6) a mono- or di-C 1-6 alkyl-carbamoyl group, or
(7) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 C 1-6 alkyl groups; and
Ring A is a 6-membered aromatic ring optionally further substituted by 1 to 3 substituents, in addition to R 4 , selected from the group consisting of
(a) a halogen atom,
(b) a C 1-6 alkyl group, and
(c) a C 1-6 alkoxy group,
or a salt thereof.
7. The compound according to claim 6 , wherein the partial structure represented by the following formula:
in the formula (I) is a partial structure represented by the following formula:
or a salt thereof.
8. The compound according to claim 1 , wherein
R 1 is
(1) a phenyl group optionally substituted by 1 to 3 substituents selected from the group consisting of
(i) a halogen atom, and
(ii) a cyano group,
(2) a C 5-6 cycloalkyl group optionally substituted by 1 to 3 hydroxy groups,
(3) a 5- or 6-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 hydroxy groups, or
(4) a C 1-6 alkyl group optionally substituted by 1 to 3 substituents selected from the group consisting of
(i) a hydroxy group, and
(ii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group;
R 2 is
(1) a hydrogen atom,
(2) a halogen atom, or
(3) a C 1-6 alkyl group;
R 3 is
(1) a hydrogen atom,
(2) a halogen atom,
(3) a cyano group,
(4) a C 1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(5) a C 1-6 alkoxy group, or
(6) a C 3-6 cycloalkyl group;
R 4 is
(1) a halogen atom,
(2) a cyano group,
(3) a C 1-6 alkyl group,
(4) a C 1-6 alkoxy group optionally substituted by 1 to 3 halogen atoms,
(5) a mono- or di-C 1-6 alkyl-carbamoyl group, or
(6) a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 C 1-6 alkyl groups; and
Ring A is a 6-membered aromatic ring optionally further substituted by 1 to 3 substituents, in addition to R 4 , selected from the group consisting of
(a) a halogen atom, and
(b) a C 1-6 alkoxy group,
or a salt thereof.
9. The compound according to claim 8 , wherein the partial structure represented by the following formula:
in the formula (I) is a partial structure represented by the following formula:
or a salt thereof.
10. The compound according to claim 1 , wherein
R 1 is
(1) a C 5-6 cycloalkyl group optionally substituted by 1 to 3 hydroxy groups, or
(2) a 5- or 6-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 hydroxy groups;
R 2 is
(1) a halogen atom, or
(2) a C 1-6 alkyl group;
R 3 is a C 1-6 alkyl group;
R 4 is
(1) a C 1-6 alkyl group,
(2) a C 1-6 alkoxy group, or
(3) a 5- or 6-membered monocyclic aromatic heterocyclic group; and
Ring A is a benzene ring or a pyridine ring, each of which is unsubstituted, in addition to R 4 ,
or a salt thereof.
11. The compound according to claim 10 , wherein the partial structure represented by the following formula:
in the formula (I) is a partial structure represented by the following formula:
or a salt thereof.
12. The compound according to claim 1 , wherein
R 1 is
(1) a cyclohexyl group substituted by one hydroxy group, or
(2) a tetrahydropyranyl group substituted by one hydroxy group;
R 2 is
(1) a halogen atom, or
(2) a C 1-6 alkyl group;
R 3 is a C 1-6 alkyl group;
R 4 is
(1) a C 1-6 alkyl group,
(2) a C 1-6 alkoxy group, or
(3) a pyrazolyl group; and
Ring A is a benzene ring or a pyridine ring, each of which is unsubstituted, in addition to R 4 ,
or a salt thereof.
13. The compound according to claim 12 , wherein the partial structure represented by the following formula:
in the formula (I) is a partial structure represented by the following formula:
or a salt thereof.
14. A medicament comprising: the compound according to claim 1 or a salt thereof; and a pharmaceutically acceptable carrier.
15. The medicament according to claim 14 , which is a cholinergic muscarinic M1 receptor positive allosteric modulator.
16. The medicament according to claim 14 , which is an agent for treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, or dementia with Lewy bodies.